Adenoma of the Islands of Langerhans

1950 ◽  
Vol 243 (8) ◽  
pp. 281-285 ◽  
Author(s):  
Herbert A. Perkins ◽  
Jane F. Desforges ◽  
Charles G. Guttas
Keyword(s):  
Islands Of Langerhans

scholarly journals MORPHOLOGICAL STUDIES IN EXPERIMENTAL CRETINISM

1913 ◽  
Vol 17 (6) ◽  
pp. 636-652 ◽  
Author(s):  
Arthur L. Tatum
Keyword(s):  
Adrenal Glands ◽  
The Body ◽  
The Other ◽  
Degenerative Changes ◽  
Morphological Studies ◽  
Cellular Changes ◽  
Anatomical Basis ◽  
Parenchymatous Organ ◽  
Islands Of Langerhans

In summarizing the findings of this paper it may be said that degenerative changes have been noted in practically every parenchymatous organ. Among these the most striking has been that of serous imbibition by the most active cells of these organs. In regard to the changes in the glands of internal secretion, the findings corroborate the statements of Cushing in regard to hypophysectomy, that removal of one gland of internal secretion results in changes in all the other glands. In this case, degenerative changes predominate in the hypophysis, thymus, ovary, and testis, while hyperplasia is seen in the islands of Langerhans and the medullas of the adrenal glands. Finally, in the rabbit athyroidism is responsible for grave degenerative changes in practically all organs and tissues of the body, and many of the symptoms of cretinism have an anatomical basis in organic cellular changes.

The Geometric Properties of Microscopic Configurations. II. Incidence and Volume of Islands of Langerhans in the Pancreas of a Monkey

Biometrika ◽  
1932 ◽  
Vol 24 (1/2) ◽  
pp. 27 ◽  
Author(s):  
William R. Thompson ◽  
Raymond Hussey ◽  
Joseph T. Matteis ◽  
William C. Meredith ◽  
George C. Wilson ◽  
...  
Keyword(s):  
Geometric Properties ◽  
Islands Of Langerhans

scholarly journals Increased EpCAM expression in malignant insulinoma: potential clinical implications

2010 ◽  
Vol 162 (2) ◽  
pp. 391-398 ◽  
Author(s):  
Andreas Raffel ◽  
Claus F Eisenberger ◽  
Kenko Cupisti ◽  
Matthias Schott ◽  
Stephan E Baldus ◽  
...  
Keyword(s):  
Malignant Tumors ◽  
Tnm Classification ◽  
Pancreatic Tissue ◽  
Stage Iiib ◽  
Disease Stage ◽  
Rank Test ◽  
Endocrine Tumors ◽  
Malignant Insulinoma ◽  
Epcam Expression ◽  
Islands Of Langerhans

ObjectiveEpCAM (CD326) is overexpressed in progenitor cells of endocrine pancreatic islands of Langerhans during fetal development and was suggested to act as a morphoregulatory molecule in pancreatic island ontogeny. We tested whether EpCAM overexpression is reactivated in insulinomas, endocrine tumors arising in the pancreas.Design/methodWe used monoclonal anti-EpCAM antibody Ber-Ep4 for immunohistochemistry on formalin-fixed and paraffin-embedded tumor material. We analyzed 53 insulinomas: 40 benign (disease stage<IIa) and 13 malignant tumors (disease stage IIIb/IV). Disease stage disposition followed new TNM classification of the European Neuroendocrine Tumor Society (ENETS) for foregut neuroendocrine tumors (2006). Additionally, ten insulinoma metastases were analyzed. Clinical follow-up was available for overall survival analysis from 49 patients. The EpCAM expression of the islands of Langerhans was classified as 2+ in healthy pancreatic tissue.ResultsIn 38% of the benign insulinomas (disease stage<IIa), we found strong (3+) EpCAM expression. In contrast, malignant insulinomas (disease stage IIIb/IV) and their metastases exhibited a strong (3+) EpCAM expression with 78 and 80% respectively, significantly more frequent (P<0.01). The malignant tissue was characterized by a significantly lower number of unstained cells and significantly higher number of 3+ stained cells. Quantitative PCR for EpCAM mRNA validated strong EpCAM expression in malignant insulinoma. Kaplan–Meier curves indicated survival disadvantage for EpCAM 3+ insulinomas, but this was not statistically significant (log-rank test).ConclusionThis first EpCAM expression study in benign/malignant insulinomas indicates that strong EpCAM expression could help to identify patients at risk for malignant disease and might be used as a therapeutic target for antibody-based therapies in patients with metastatic insulinoma.

Sign in / Sign up

Export Citation Format

Share Document